Ultra-high-throughput PCR testing system for SARS-CoV-2 detection

Test up to 150,000 patient samples per day on a proven molecular genomics testing platform with unmatched capacity

It’s time to redefine large-scale COVID-19 testing. For labs ready to scale to support mass testing, LGC Biosearch Technologies offers an ultra-high-throughput (uHTP) end-point PCR testing system for SARS-CoV-2 detection.

The Biosearch Technologies workflow combines the Nexar™ industrial scale, automated end-point PCR testing platform with our robust, high-quality testing reagent components. UgenTec’s FastFinder software seamlessly integrates with Biosearch Technologies’ instrumentation to provide full traceability of the sample down to individual wells on the Array Tape™ consumable, which allows the user to easily pull up a sample’s status.

See if ultra-high-throughput is right for your lab

Interested in

ultra-high-throughput?

Sample
collection

Sample receipt
and preparation

Lysis and
inactivation

Amplification
and detection

Data interpretation
and workflow
management

Explore the ultra-high-throughput PCR testing workflow

Why choose Biosearch Technologies' SARS-CoV-2 testing system?

- Good for screening symptomatic and asymptomatic individuals.

- Compatible with anterior nares specimens self-collected in a non-medical setting or by a healthcare professional within a healthcare setting.

- Easy dry swab collection device that’s safe for handling, better for shipping, and automation-friendly.

- Extraction-free process without compromising sensitivity of a 250 cp/swab limit of detection (LoD).

The Biosearch Technologies SARS-CoV-2 testing system from LGC

Biosearch Technologies’ SARS-CoV-2 testing workflow can expand testing capacity to as many as 150,000 samples per day with minimal need for additional staff, instrumentation, or lab space. This optimised package of hardware, reagents, consumables and software includes: